{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:38:33Z","timestamp":1784875113304,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Vascular Surgery"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1053\/j.semvascsurg.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T01:58:48Z","timestamp":1649987928000},"page":"124-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A comprehensive review on antithrombotic therapy for peripheral artery disease"],"prefix":"10.1053","volume":"35","author":[{"given":"Ryan","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabbia","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeniann","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9901","key":"10.1053\/j.semvascsurg.2022.04.004_bib0001","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0002","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejvs.2013.03.024","article-title":"Short and long term mortality rates after a lower limb amputation","volume":"46","author":"Fortington","year":"2013","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"10.1053\/j.semvascsurg.2022.04.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2005.11.004","article-title":"The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design","volume":"151","author":"Ohman","year":"2006","journal-title":"Am Heart J"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0004","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/archinte.163.16.1939","article-title":"The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study","volume":"163","author":"Murabito","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0005","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0006","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCULATIONAHA.119.039773","article-title":"Acute limb ischemia in peripheral artery disease","volume":"140","author":"Hess","year":"2019","journal-title":"Circulation"},{"issue":"3S\u2013125S","key":"10.1053\/j.semvascsurg.2022.04.004_bib0007","first-page":"e40","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia [published correction appears in J Vasc Surg. 2019 Aug;70(2):662]","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0008","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9149(97)00904-1","article-title":"Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)","volume":"81","author":"Pedersen","year":"1998","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1053\/j.semvascsurg.2022.04.004_bib0010","first-page":"e686","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"issue":"3 suppl","key":"10.1053\/j.semvascsurg.2022.04.004_bib0011","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication [published correction appears in J Vasc Surg. 2015 May;61(5):1382]","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0012","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jacc.2018.03.483","article-title":"Antithrombotic therapy for peripheral artery disease: recent advances","volume":"71","author":"Hussain","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0013","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.atherosclerosis.2008.10.023","article-title":"Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"204","author":"Cacoub","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0014","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/CIRCULATIONAHA.112.108787","article-title":"Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains","volume":"126","author":"Subherwal","year":"2012","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0017","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0018","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0741-5214(03)00129-0","article-title":"Platelet activation is increased in peripheral arterial disease","volume":"38","author":"Cassar","year":"2003","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0019","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jvs.2007.05.039","article-title":"Platelet activation increases with the severity of peripheral arterial disease: Implications for clinical management","volume":"46","author":"Rajagopalan","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0020","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","article-title":"Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions","volume":"109","author":"Undas","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0021","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0022","unstructured":"Draft Recommendation: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication. US Preventive Services Taskforce. October 12, 2021. Accessed February 22, 2022. https:\/\/www.uspreventiveservicestaskforce.org"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0023","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/CIRCULATIONAHA.117.028888","article-title":"Aspirin monotherapy should note be recommended for cardioprotection in patients with symptomatic peripheral artery disease","volume":"136","author":"Brass","year":"2017","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0024","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2796.2006.01763.x","article-title":"Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial","volume":"261","author":"Catalano","year":"2007","journal-title":"J Intern Med"},{"issue":"9038","key":"10.1053\/j.semvascsurg.2022.04.004_bib0025","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0026","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0027","unstructured":"Ticagrelor is the best antiplatelet agent for pretreatment in patients with ACS. American College of Cardiology. Accessed February 22, 2022. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2016\/06\/13\/10\/01\/ticagrelor-is-the-best-antiplatelet-agent-for-pretreatment-in-patients-with-acs"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0028","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MBC.0000000000000406","article-title":"Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?","volume":"27","author":"Samo\u0161","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0029","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jvs.2017.07.065","article-title":"Review of aspirin and clopidogrel resistance in peripheral arterial disease","volume":"66","author":"Guirgis","year":"2017","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0030","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.115.019355","volume":"133","author":"Bonaca","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0031","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ahj.2014.06.017","article-title":"Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)","volume":"168","author":"Jones","year":"2014","journal-title":"Am Heart J"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0032","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0033","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/2047487314533215","article-title":"Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial","volume":"22","author":"Patel","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0034","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.116.024637","volume":"134","author":"Bonaca","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0035","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jcin.2019.08.006","article-title":"Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease","volume":"12","author":"Cho","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0036","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.jcin.2019.09.030","article-title":"A brief history of the proper time for antiplatelet therapy in peripheral revascularization","volume":"12","author":"Vlachopoulos","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0037","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"issue":"10073","key":"10.1053\/j.semvascsurg.2022.04.004_bib0038","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0039","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jacc.2017.02.017","article-title":"The proliferation of scoring systems: trying to keep our heads out of the clouds","volume":"69","author":"Fuster","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0040","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamacardio.2016.2811","article-title":"Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial","volume":"1","author":"Franzone","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0041","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0042","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0043","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.282.21.2058","article-title":"Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis","volume":"282","author":"Anand","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0044","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0045","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.118.033580","article-title":"Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease: focus on the compass trial","volume":"139","author":"Gurbel","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0046","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0047","unstructured":"Patel S, Singh R, Preuss CV, et al. Warfarin. StatPearls Publishing; 2022"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0048","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0049","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/ATVBAHA.119.312142","article-title":"Evidence-based medical management of peripheral artery disease","volume":"40","author":"Bevan","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9201","key":"10.1053\/j.semvascsurg.2022.04.004_bib0050","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery: the Dutch Bypass Oral Anticoagulants or Aspirin study","volume":"355","author":"Study Group","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0051","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0052","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0053","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s11239-021-02417-3","article-title":"The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Costa","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0054","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ahj.2020.06.010","article-title":"Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial","volume":"227","author":"Biagioni","year":"2020","journal-title":"Am Heart J"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0055","doi-asserted-by":"crossref","first-page":"e09","DOI":"10.15420\/ver.2019.10","article-title":"Anticoagulation in peripheral artery disease: are we there yet?","volume":"3","author":"Cannavale","year":"2020","journal-title":"Vasc Endovasc Rev"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0056","doi-asserted-by":"crossref","unstructured":"Lopes RD, Steffel J, Di Fusco M, et al. Effectiveness and safety of anticoagulants in adults with non-valvular atrial fibrillation and concomitant coronary\/peripheral artery disease. Am J Med 2018;131:1075\u201385.e4.","DOI":"10.1016\/j.amjmed.2018.05.007"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0057","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejvs.2004.11.011","article-title":"Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia\u2013a randomised placebo-controlled double blind multicentre trial","volume":"29","author":"Jiveg\u00e5rd","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1053\/j.semvascsurg.2022.04.004_bib0058","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.2018.5422","article-title":"Antithrombotic therapy for peripheral artery disease in 2018","volume":"319","author":"Hess","year":"2018","journal-title":"JAMA"}],"container-title":["Seminars in Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796722000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796722000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:39:05Z","timestamp":1760247545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895796722000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0895796722000199"],"URL":"https:\/\/doi.org\/10.1053\/j.semvascsurg.2022.04.004","relation":{},"ISSN":["0895-7967"],"issn-type":[{"value":"0895-7967","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review on antithrombotic therapy for peripheral artery disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semvascsurg.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}